Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$11.29 USD
+0.04 (0.36%)
Updated May 23, 2024 12:44 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 41 - 60 ( 363 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PFE and MRNA COVID-19 Vaccine Interims Are Strong, More Competition Coming
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 DNA Vaccine Phase 2 Trial Initiated; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PFE and MRNA COVID-19 Vaccine Interims Are Strong, More Competition Coming
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: 3100 Phase 3 Data Now in 1H21, 5401 Data at SNO, Upgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partial Hold Imposed on Planned COVID-19 Vaccine Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2/3 Clinical Hold Costs Precious Time Given Competition - PT to $8
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vaccine Manufacturing Capacity Strengthened; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Years of Cash, Not Expecting INO-4800 to Pan Out Against Competition
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-4800 Protects Primates in COVID-19 Challenge Study; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Designation Granted to INO-3107; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in South Korean COVID-19 Vaccine Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to Sell - Still Unimpressed with INO-4800''s Ability to Compete
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J